Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib
| dc.contributor.author | Vogel, C. | |
| dc.contributor.author | Chan, Arlene | |
| dc.contributor.author | Gril, B. | |
| dc.contributor.author | Kim, S. | |
| dc.contributor.author | Kurebayashi, J. | |
| dc.contributor.author | Liu, L. | |
| dc.contributor.author | Lu, Y. | |
| dc.contributor.author | Moon, H. | |
| dc.date.accessioned | 2017-01-30T11:41:38Z | |
| dc.date.available | 2017-01-30T11:41:38Z | |
| dc.date.created | 2014-11-19T01:13:19Z | |
| dc.date.issued | 2010 | |
| dc.identifier.citation | Vogel, C. and Chan, A. and Gril, B. and Kim, S. and Kurebayashi, J. and Liu, L. and Lu, Y. et al. 2010. Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib. Japanese Journal of Clinical Oncology. 40 (11): pp. 999-1013. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/14131 | |
| dc.publisher | Oxford University Press | |
| dc.title | Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib | |
| dc.type | Journal Article | |
| dcterms.source.volume | 40 | |
| dcterms.source.number | 11 | |
| dcterms.source.startPage | 999 | |
| dcterms.source.endPage | 1013 | |
| dcterms.source.issn | 0368-2811 | |
| dcterms.source.title | Japanese Journal of Clinical Oncology | |
| curtin.accessStatus | Fulltext not available |